Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
JSPR
Upturn stock ratingUpturn stock rating

Jasper Therapeutics Inc (JSPR)

Upturn stock ratingUpturn stock rating
$3.03
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: JSPR (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

11 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $20.12

1 Year Target Price $20.12

Analysts Price Target For last 52 week
$20.12 Target price
52w Low $2.27
Current$3.03
52w High $26.05

Analysis of Past Performance

Type Stock
Historic Profit -6.2%
Avg. Invested days 31
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 45.52M USD
Price to earnings Ratio -
1Y Target Price 20.12
Price to earnings Ratio -
1Y Target Price 20.12
Volume (30-day avg) 11
Beta 2.71
52 Weeks Range 2.27 - 26.05
Updated Date 08/15/2025
52 Weeks Range 2.27 - 26.05
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -6.05

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -73.3%
Return on Equity (TTM) -146.87%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 8162029
Price to Sales(TTM) -
Enterprise Value 8162029
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -3.42
Shares Outstanding 15022100
Shares Floating 9892753
Shares Outstanding 15022100
Shares Floating 9892753
Percent Insiders 1.27
Percent Institutions 84.25

ai summary icon Upturn AI SWOT

Jasper Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Jasper Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of conditioning therapies for hematopoietic stem cell transplantation (HSCT) and gene therapy. It was incorporated in 2019 and went public in 2022 via a SPAC merger. The company aims to improve outcomes for patients undergoing HSCT by reducing toxicity and improving engraftment.

business area logo Core Business Areas

  • Hematopoietic Stem Cell Transplantation (HSCT) Conditioning: Developing and commercializing therapies to improve HSCT outcomes by reducing toxicity and enhancing engraftment.
  • Gene Therapy Conditioning: Exploring the use of their conditioning therapies to enable safer and more effective gene therapy.

leadership logo Leadership and Structure

The leadership team includes Ronald Martell (CEO), Edwin Stone (Chief Medical Officer), and Jeet Mahal (Chief Financial Officer). The company operates with a focus on research and development, clinical trials, and potential commercialization of its pipeline products.

Top Products and Market Share

overview logo Key Offerings

  • Busamphan: Busamphan is a myeloconditioning agent, a generic name of a therapeutic used to clear bone marrow to allow the patient's body to accept new stem cells, either from their own cells or from a donor's cells. Market share data is not publicly available. Competitors include Bristol Myers Squibb(BUSULFEX).
  • Briquilimab: Briquilimab is Jasper's lead product candidate, a monoclonal antibody targeting c-KIT, designed to enable stem cell transplantations without the need for traditional high-intensity chemotherapy or radiation. Market share data is not yet available as it is still in clinical trials. Competitors may emerge as other conditioning regimens are developed.

Market Dynamics

industry overview logo Industry Overview

The HSCT and gene therapy conditioning market is growing, driven by advancements in these fields and the increasing need for safer and more effective conditioning regimens. There is a trend toward reduced-intensity conditioning to minimize toxicity.

Positioning

Jasper Therapeutics aims to be a leader in HSCT and gene therapy conditioning by developing novel therapies that reduce toxicity and improve outcomes. Their competitive advantage lies in their c-KIT targeting antibody, briquilimab.

Total Addressable Market (TAM)

The TAM for HSCT and gene therapy conditioning is estimated to be in the billions of dollars, growing with the expansion of these therapies. Jasper is positioned to capture a significant share of this market if briquilimab is successful.

Upturn SWOT Analysis

Strengths

  • Novel c-KIT targeting antibody (briquilimab)
  • Experienced leadership team
  • Focus on addressing unmet needs in HSCT and gene therapy
  • Strong intellectual property portfolio

Weaknesses

  • Clinical trial risks and uncertainties
  • Limited financial resources
  • Reliance on a single lead product candidate
  • Small company size

Opportunities

  • Potential for briquilimab to become a standard of care in HSCT conditioning
  • Expansion of gene therapy applications
  • Partnerships with larger pharmaceutical companies
  • Development of additional conditioning therapies

Threats

  • Competition from established pharmaceutical companies
  • Regulatory hurdles
  • Clinical trial failures
  • Changes in reimbursement policies

Competitors and Market Share

competitor logo Key Competitors

  • BMS (BMY)
  • Sanofi (SNY)
  • Gilead (GILD)

Competitive Landscape

Jasper Therapeutics faces intense competition from established pharmaceutical companies with greater resources and broader product portfolios. Jasper's competitive advantage lies in its novel c-KIT targeting antibody, briquilimab, if it proves clinically effective.

Growth Trajectory and Initiatives

Historical Growth: Growth has been driven by advancement of briquilimab through clinical trials. Since a clinical-stage company, a rapid increase in stock valuation depends on clinical trial results.

Future Projections: Future growth is dependent on the successful completion of clinical trials, regulatory approvals, and commercialization of briquilimab and other pipeline products. Analyst estimates vary widely depending on the perceived probability of success.

Recent Initiatives: Recent initiatives include enrollment in ongoing clinical trials for briquilimab and exploration of partnerships.

Summary

Jasper Therapeutics is a clinical-stage biopharmaceutical company with a promising lead candidate, briquilimab, targeting a significant unmet need in HSCT and gene therapy conditioning. Its success hinges on positive clinical trial outcomes and securing regulatory approvals, facing inherent risks in drug development. The company needs to carefully manage its financial resources to support its clinical programs and achieve commercialization.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC filings (10-K, 10-Q), company press releases, investor presentations, industry reports, analyst reports

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share estimations are based on available data and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Jasper Therapeutics Inc

Exchange NASDAQ
Headquaters Redwood City, CA, United States
IPO Launch date 2021-09-24
President, CEO & Director Mr. Ronald A. Martell
Sector Healthcare
Industry Biotechnology
Full time employees 64
Full time employees 64

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.